Boehringer Ingelheim reported that survodutide, its investigational glucagon/GLP-1 dual agonist, produced an average body weight reduction of 16.6% over 76 weeks in adults with obesity or overweight without type 2 diabetes, meeting both co-primary endpoints in the Phase III SYNCHRONIZE-1 trial and positioning the molecule as a late-stage contender in an obesity market already shaped by approved GLP-1-based therapies.
SYNCHRONIZE-1 Trial Results: Design and Population
The SYNCHRONIZE-1 trial (NCT06066515) is a Phase III, double-blind, placebo-controlled study enrolling 725 adults living with obesity or overweight without type 2 diabetes, evaluating weekly subcutaneous injections of survodutide at doses of 3.6 mg or 6.0 mg versus placebo over 76 weeks.
Key Efficacy Findings
Against a placebo arm that recorded 3.2% mean weight loss, survodutide-treated participants achieved up to 16.6% average body weight reduction at Week 76 using the efficacy estimand (p<0.0001). On the trial's second co-primary endpoint, 85.1% of participants on survodutide achieved at least 5% body weight reduction, compared with 38.8% on placebo (p<0.0001). In absolute terms, participants lost up to an average of 39.2 lb (17.8 kg) from baseline. A key secondary endpoint measuring waist circumference — a marker associated with visceral fat and cardiometabolic risk — also reached statistical significance versus placebo, though Boehringer did not disclose the numeric change in its topline statement. Initial analysis indicated that weight reduction was driven predominantly by fat tissue loss, with lean mass contributing only a small proportion of the total.
Gastrointestinal events occurred as expected for the GLP-1 drug class, with discontinuations more frequent during the dose-escalation phase. The company described these events as mild to moderate in severity and transient, reporting no new safety signals beyond those anticipated for GLP-1-based agents.
Survodutide Weight Loss in Competitive Context: Where the Molecule Sits
The obesity pharmacotherapy landscape against which Boehringer is advancing survodutide is defined by two established agents. Semaglutide 2.4 mg (Wegovy [semaglutide]), a GLP-1 receptor agonist developed by Novo Nordisk, received FDA approval in 2021 and demonstrated approximately 14.9% mean weight loss in the STEP 1 trial. Tirzepatide (Zepbound [tirzepatide]), Eli Lilly's dual GLP-1/GIP receptor agonist, subsequently reported up to 22.5% mean weight loss in the SURMOUNT-1 trial and carries FDA approval for obesity. Cross-trial comparisons are limited by differences in population, trial design, duration, and estimand methodology, and no head-to-head data exist between survodutide and either approved agent.
What distinguishes survodutide mechanistically is its receptor pairing. Rather than combining GLP-1R with the glucose-dependent insulinotropic polypeptide receptor (GIPR) as tirzepatide does, survodutide activates GLP-1R alongside the glucagon receptor (GCGR). GLP-1R agonism reduces appetite and increases satiety, effects shared across the class. GCGR activation is thought to act more directly on the liver — reducing hepatic fat, modulating metabolic function, and potentially resolving inflammation and fibrosis. That hepatic dimension is what gives survodutide a strategic profile that extends beyond weight reduction alone, into metabolic dysfunction-associated steatohepatitis (MASH), a liver disease affecting an estimated 34% of people living with obesity.